Devimistat

Drug Overview

Devimistat is a first-in-class investigational medication that represents a new frontier in cancer therapy. Unlike traditional chemotherapy that attacks a cell’s DNA, devimistat is a “Smart Drug” that targets the very engine of the cancer cell—its metabolism. By disrupting how cancer cells produce energy, devimistat seeks to weaken them and make them more vulnerable to other treatments.

Here are the key details about this agent:

• Generic Name: Devimistat (also known as CPI-613).
• US Brand Names: None currently. It is an investigational drug.
• Drug Class: Mitochondrial Metabolism Inhibitor / Lipoate Analog.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. It has received “Orphan Drug” designation for several rare cancers but is not yet approved for general use.

What Is It and How Does It Work? (Mechanism of Action)

To understand devimistat, think of a cancer cell like a high-speed car. To move so fast, the car needs a huge amount of fuel. Devimistat works by “clogging the fuel line” of the cancer cell. Specifically, it targets the mitochondria, which are known as the “powerhouse” of the cell.

Targeting the Krebs Cycle

At the molecular level, devimistat mimics a substance called lipoate. Lipoate is a helper molecule for two very important enzymes: Pyruvate Dehydrogenase (PDH) and Alpha-Ketoglutarate Dehydrogenase (KGDH). These enzymes are the gatekeepers of the Krebs Cycle, the process cells use to create energy.

The Molecular Trick

Devimistat tricks the cancer cell in a very clever way:

1. Enzyme Inhibition: It binds to the PDH and KGDH enzymes.
2. Starvation Signal: By binding to these enzymes, devimistat sends a false signal to the cell that it has too much energy.
3. Shutting Down: In response to this false signal, the cancer cell shuts down its energy-producing pathways.
4. Energy Crisis: Because cancer cells are much more “hungry” than healthy cells, this sudden energy loss causes massive stress. The cancer cell becomes “starved” and often enters a state of programmed cell death (apoptosis).

Because healthy cells are more flexible and can find energy elsewhere, devimistat is designed to hurt cancer cells much more than it hurts your body’s normal cells.

FDA Approved Clinical Indications

As an investigational drug, devimistat does not have official FDA-approved uses for the general public yet. However, it is being tested in advanced clinical trials for the following conditions:

Oncological Uses (In Clinical Trials):

• Metastatic Pancreatic Cancer: Often studied in combination with the modified FOLFIRINOX chemotherapy regimen.
• Acute Myeloid Leukemia (AML): Specifically for older patients or those whose cancer has returned (relapsed).
• Peripheral T-Cell Lymphoma: Studied as a potential new option for rare blood cancers.
• Myelodysplastic Syndromes (MDS): Used in trials to help patients whose bone marrow does not produce enough healthy blood cells.

Non-oncological Uses:

• There are currently no non-cancer uses for devimistat.

Dosage and Administration Protocols

Devimistat is given through a needle into a vein (IV). It is almost always given as part of a combination therapy, meaning it is used alongside other cancer medicines to create a “double-hit” effect.

Note: In cases of severe renal (kidney) or hepatic (liver) insufficiency, the medical team will monitor blood levels very closely. Since the drug is processed largely in the liver, significant damage there requires a lower dose.

Clinical Efficacy and Research Results

Clinical research from 2020 to 2025 has provided important data on how devimistat helps patients.

• Pancreatic Cancer Data (AVENGER 500 Trial): This major study looked at devimistat combined with chemotherapy. While it did not reach its “primary goal” of significantly extending overall survival for every patient, researchers found that a specific group of patients responded very well, leading to new studies on how to find the best candidates for this drug.
• Acute Myeloid Leukemia (AML): In phase 2 trials, devimistat combined with high-dose chemotherapy showed a “Complete Remission” rate (the disappearance of all signs of cancer) in approximately 30% to 50% of older patients with relapsed disease. This is considered a promising result for a difficult-to-treat group.
• Survival Rates: Ongoing data suggests that when devimistat works, it can stabilize the disease for several months longer than chemotherapy alone in specific T-cell lymphomas.

Safety Profile and Side Effects

Because devimistat is usually given with other chemotherapy, it can be hard to tell which medicine causes which side effect. However, doctors have identified a specific pattern for devimistat.

Black Box Warning

• There is no FDA Black Box Warning for devimistat. As an investigational agent, its safety is still being monitored in clinical trials.

Common Side Effects (>10%)

• Nausea and Vomiting: Often manageable with standard anti-sickness medications.
• Fatigue: A general feeling of tiredness or weakness.
• Diarrhea: Changes in bowel movements.
• Electrolyte Changes: Changes in levels of salt or minerals in the blood (like low potassium).

Serious Adverse Events

• Neutropenia: A drop in white blood cells which can lead to a higher risk of infection.
• Thrombocytopenia: A drop in platelets which can lead to easier bruising or bleeding.
• Infusion Reactions: Some patients may experience a rash or difficulty breathing during the infusion.

Management Strategies

• For Low Blood Counts: Doctors may use “growth factors” (injections) to help the body make more blood cells.
• For Infusion Reactions: The medical team may slow down the infusion or give “pre-meds” like antihistamines before the next dose.

Research Areas

In the field of Immunotherapy, researchers are looking at how devimistat changes the “microenvironment” of a tumor. Because devimistat starves cancer cells, it might make it easier for the body’s own immune system to find and attack them. There are currently small studies looking at combining devimistat with “Checkpoint Inhibitors” (drugs that help the immune system recognize cancer). Additionally, in Regenerative Medicine, scientists are studying if metabolic inhibitors can protect healthy stem cells while specifically killing cancer-causing stem cells.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Complete Blood Count (CBC): To check your levels of white cells, red cells, and platelets.
• Metabolic Panel: To check your kidney and liver function.
• EKG: To check the health of your heart before starting a new medicine.

Precautions During Treatment

• Hydration: Drink plenty of fluids (water and juice) to help your kidneys flush out the waste products from the cancer cells.
• Infection Control: Since your immune system may be weaker, avoid large crowds or people who are sick.

“Do’s and Don’ts” List

• DO tell your doctor immediately if you develop a fever over 100.4°F (38°C).
• DO keep a log of your appetite and any changes in your energy levels.
• DON’T start any new herbal supplements or vitamins without checking with your oncologist, as they can interfere with how devimistat works.
• DON’T ignore signs of bleeding, like blood in your urine or gums that bleed easily.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Devimistat is an investigational drug and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.